J GENE MED 润色咨询

JOURNAL OF GENE MEDICINE

出版年份:1999 年文章数:785 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:7.2% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2121135, encodeId=5b6721211359d, content=请问各位初审Under Review多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf9c5290959, createdName=14862b90m09(暂无昵称), createdTime=Wed Mar 22 16:27:37 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=590987, encodeId=667d59098ec9, content=投了篇生信,被转到别的杂志。最后还是拒绝。写给大家做个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=560e5151026, createdName=14697858m50(暂无昵称), createdTime=Sat May 16 00:00:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093227, encodeId=8b7a109322e8c, content=SCI期刊是如何分区的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188004, encodeId=0e802188004e9, content=审稿速度:6.0<br>偏重的研究方向:胰腺炎<br>经验分享:审稿速度非常慢,一审2个月,2审3个月还在进行中,且发邮件不回复,太难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ce1740495, createdName=扒坏蛋糕, createdTime=Sun Feb 18 17:08:21 CST 2024, time=2024-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=501404, encodeId=28c850140423, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:4个figure,一审周期约3个月,大修三个月后返回很快小修,小修几天返回很快接受,从投稿到接受约5个月左右……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Feb 27 11:19:00 CST 2014, time=2014-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560053, encodeId=7a06560053e1, content=不选择onlineopen就不收费吗?<span class="quote">欢乐的树博士 2017-07-21 发表::<br>研究方向:药物载体;基因; 接收率:约75% 审稿时间:约2个月 两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。</span><span class="quote">欢乐的树博士 2017-07-21 15:04:00 发表:<br>两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 <br> 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 <br> 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。</span>, beContent=欢乐的树博士 2017-07-21 发表:: 研究方向:药物载体;基因; 接收率:约75% 审稿时间:约2个月 两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0dfa2208657, createdName=120ce422m02(暂无昵称), createdTime=Mon Aug 13 00:00:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093228, encodeId=256010932288b, content=选刊时需结合分区进行吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2194959, encodeId=067621949595d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:妇科肿瘤<br>经验分享:投了第二天旧送审了,2.5送审,3.11悲剧,理由:找了三十个审稿人,没人审稿,真无语。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0c02582555, createdName=zhangqiccmu, createdTime=Sun Mar 24 03:11:43 CST 2024, time=2024-03-24, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2107636, encodeId=b4a2210e6362e, content=挺好的杂志,做外泌体miRNA治疗方向,投了别的五六分期刊都被拒了,投这个至少给外审了,希望能有好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bea5414925, createdName=ms1000001212608631, createdTime=Tue Dec 27 10:54:27 CST 2022, time=2022-12-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1003273, encodeId=9e0910032e370, content=偏重的研究方向:基因<br>经验分享:cancer medicine推荐转投,确定转投以后好几天一直没消息呢,大家有类似经历吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Wed Jul 28 11:04:37 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
    2023-03-22 14862b90m09(暂无昵称) 来自上海

    请问各位初审Under Review多久

    3

    展开3条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2121135, encodeId=5b6721211359d, content=请问各位初审Under Review多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf9c5290959, createdName=14862b90m09(暂无昵称), createdTime=Wed Mar 22 16:27:37 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=590987, encodeId=667d59098ec9, content=投了篇生信,被转到别的杂志。最后还是拒绝。写给大家做个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=560e5151026, createdName=14697858m50(暂无昵称), createdTime=Sat May 16 00:00:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093227, encodeId=8b7a109322e8c, content=SCI期刊是如何分区的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188004, encodeId=0e802188004e9, content=审稿速度:6.0<br>偏重的研究方向:胰腺炎<br>经验分享:审稿速度非常慢,一审2个月,2审3个月还在进行中,且发邮件不回复,太难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ce1740495, createdName=扒坏蛋糕, createdTime=Sun Feb 18 17:08:21 CST 2024, time=2024-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=501404, encodeId=28c850140423, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:4个figure,一审周期约3个月,大修三个月后返回很快小修,小修几天返回很快接受,从投稿到接受约5个月左右……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Feb 27 11:19:00 CST 2014, time=2014-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560053, encodeId=7a06560053e1, content=不选择onlineopen就不收费吗?<span class="quote">欢乐的树博士 2017-07-21 发表::<br>研究方向:药物载体;基因; 接收率:约75% 审稿时间:约2个月 两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。</span><span class="quote">欢乐的树博士 2017-07-21 15:04:00 发表:<br>两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 <br> 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 <br> 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。</span>, beContent=欢乐的树博士 2017-07-21 发表:: 研究方向:药物载体;基因; 接收率:约75% 审稿时间:约2个月 两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0dfa2208657, createdName=120ce422m02(暂无昵称), createdTime=Mon Aug 13 00:00:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093228, encodeId=256010932288b, content=选刊时需结合分区进行吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2194959, encodeId=067621949595d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:妇科肿瘤<br>经验分享:投了第二天旧送审了,2.5送审,3.11悲剧,理由:找了三十个审稿人,没人审稿,真无语。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0c02582555, createdName=zhangqiccmu, createdTime=Sun Mar 24 03:11:43 CST 2024, time=2024-03-24, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2107636, encodeId=b4a2210e6362e, content=挺好的杂志,做外泌体miRNA治疗方向,投了别的五六分期刊都被拒了,投这个至少给外审了,希望能有好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bea5414925, createdName=ms1000001212608631, createdTime=Tue Dec 27 10:54:27 CST 2022, time=2022-12-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1003273, encodeId=9e0910032e370, content=偏重的研究方向:基因<br>经验分享:cancer medicine推荐转投,确定转投以后好几天一直没消息呢,大家有类似经历吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Wed Jul 28 11:04:37 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
    2020-05-16 14697858m50(暂无昵称)

    投了篇生信,被转到别的杂志。最后还是拒绝。写给大家做个参考

    2

    展开2条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2121135, encodeId=5b6721211359d, content=请问各位初审Under Review多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf9c5290959, createdName=14862b90m09(暂无昵称), createdTime=Wed Mar 22 16:27:37 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=590987, encodeId=667d59098ec9, content=投了篇生信,被转到别的杂志。最后还是拒绝。写给大家做个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=560e5151026, createdName=14697858m50(暂无昵称), createdTime=Sat May 16 00:00:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093227, encodeId=8b7a109322e8c, content=SCI期刊是如何分区的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188004, encodeId=0e802188004e9, content=审稿速度:6.0<br>偏重的研究方向:胰腺炎<br>经验分享:审稿速度非常慢,一审2个月,2审3个月还在进行中,且发邮件不回复,太难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ce1740495, createdName=扒坏蛋糕, createdTime=Sun Feb 18 17:08:21 CST 2024, time=2024-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=501404, encodeId=28c850140423, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:4个figure,一审周期约3个月,大修三个月后返回很快小修,小修几天返回很快接受,从投稿到接受约5个月左右……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Feb 27 11:19:00 CST 2014, time=2014-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560053, encodeId=7a06560053e1, content=不选择onlineopen就不收费吗?<span class="quote">欢乐的树博士 2017-07-21 发表::<br>研究方向:药物载体;基因; 接收率:约75% 审稿时间:约2个月 两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。</span><span class="quote">欢乐的树博士 2017-07-21 15:04:00 发表:<br>两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 <br> 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 <br> 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。</span>, beContent=欢乐的树博士 2017-07-21 发表:: 研究方向:药物载体;基因; 接收率:约75% 审稿时间:约2个月 两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0dfa2208657, createdName=120ce422m02(暂无昵称), createdTime=Mon Aug 13 00:00:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093228, encodeId=256010932288b, content=选刊时需结合分区进行吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2194959, encodeId=067621949595d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:妇科肿瘤<br>经验分享:投了第二天旧送审了,2.5送审,3.11悲剧,理由:找了三十个审稿人,没人审稿,真无语。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0c02582555, createdName=zhangqiccmu, createdTime=Sun Mar 24 03:11:43 CST 2024, time=2024-03-24, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2107636, encodeId=b4a2210e6362e, content=挺好的杂志,做外泌体miRNA治疗方向,投了别的五六分期刊都被拒了,投这个至少给外审了,希望能有好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bea5414925, createdName=ms1000001212608631, createdTime=Tue Dec 27 10:54:27 CST 2022, time=2022-12-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1003273, encodeId=9e0910032e370, content=偏重的研究方向:基因<br>经验分享:cancer medicine推荐转投,确定转投以后好几天一直没消息呢,大家有类似经历吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Wed Jul 28 11:04:37 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
    2021-12-27 ms6000000264964247

    SCI期刊是如何分区的?

    2

    展开2条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2121135, encodeId=5b6721211359d, content=请问各位初审Under Review多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf9c5290959, createdName=14862b90m09(暂无昵称), createdTime=Wed Mar 22 16:27:37 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=590987, encodeId=667d59098ec9, content=投了篇生信,被转到别的杂志。最后还是拒绝。写给大家做个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=560e5151026, createdName=14697858m50(暂无昵称), createdTime=Sat May 16 00:00:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093227, encodeId=8b7a109322e8c, content=SCI期刊是如何分区的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188004, encodeId=0e802188004e9, content=审稿速度:6.0<br>偏重的研究方向:胰腺炎<br>经验分享:审稿速度非常慢,一审2个月,2审3个月还在进行中,且发邮件不回复,太难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ce1740495, createdName=扒坏蛋糕, createdTime=Sun Feb 18 17:08:21 CST 2024, time=2024-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=501404, encodeId=28c850140423, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:4个figure,一审周期约3个月,大修三个月后返回很快小修,小修几天返回很快接受,从投稿到接受约5个月左右……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Feb 27 11:19:00 CST 2014, time=2014-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560053, encodeId=7a06560053e1, content=不选择onlineopen就不收费吗?<span class="quote">欢乐的树博士 2017-07-21 发表::<br>研究方向:药物载体;基因; 接收率:约75% 审稿时间:约2个月 两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。</span><span class="quote">欢乐的树博士 2017-07-21 15:04:00 发表:<br>两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 <br> 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 <br> 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。</span>, beContent=欢乐的树博士 2017-07-21 发表:: 研究方向:药物载体;基因; 接收率:约75% 审稿时间:约2个月 两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0dfa2208657, createdName=120ce422m02(暂无昵称), createdTime=Mon Aug 13 00:00:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093228, encodeId=256010932288b, content=选刊时需结合分区进行吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2194959, encodeId=067621949595d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:妇科肿瘤<br>经验分享:投了第二天旧送审了,2.5送审,3.11悲剧,理由:找了三十个审稿人,没人审稿,真无语。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0c02582555, createdName=zhangqiccmu, createdTime=Sun Mar 24 03:11:43 CST 2024, time=2024-03-24, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2107636, encodeId=b4a2210e6362e, content=挺好的杂志,做外泌体miRNA治疗方向,投了别的五六分期刊都被拒了,投这个至少给外审了,希望能有好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bea5414925, createdName=ms1000001212608631, createdTime=Tue Dec 27 10:54:27 CST 2022, time=2022-12-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1003273, encodeId=9e0910032e370, content=偏重的研究方向:基因<br>经验分享:cancer medicine推荐转投,确定转投以后好几天一直没消息呢,大家有类似经历吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Wed Jul 28 11:04:37 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
    2024-02-18 扒坏蛋糕 来自上海

    审稿速度:6.0
    偏重的研究方向:胰腺炎
    经验分享:审稿速度非常慢,一审2个月,2审3个月还在进行中,且发邮件不回复,太难了

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2121135, encodeId=5b6721211359d, content=请问各位初审Under Review多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf9c5290959, createdName=14862b90m09(暂无昵称), createdTime=Wed Mar 22 16:27:37 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=590987, encodeId=667d59098ec9, content=投了篇生信,被转到别的杂志。最后还是拒绝。写给大家做个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=560e5151026, createdName=14697858m50(暂无昵称), createdTime=Sat May 16 00:00:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093227, encodeId=8b7a109322e8c, content=SCI期刊是如何分区的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188004, encodeId=0e802188004e9, content=审稿速度:6.0<br>偏重的研究方向:胰腺炎<br>经验分享:审稿速度非常慢,一审2个月,2审3个月还在进行中,且发邮件不回复,太难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ce1740495, createdName=扒坏蛋糕, createdTime=Sun Feb 18 17:08:21 CST 2024, time=2024-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=501404, encodeId=28c850140423, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:4个figure,一审周期约3个月,大修三个月后返回很快小修,小修几天返回很快接受,从投稿到接受约5个月左右……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Feb 27 11:19:00 CST 2014, time=2014-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560053, encodeId=7a06560053e1, content=不选择onlineopen就不收费吗?<span class="quote">欢乐的树博士 2017-07-21 发表::<br>研究方向:药物载体;基因; 接收率:约75% 审稿时间:约2个月 两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。</span><span class="quote">欢乐的树博士 2017-07-21 15:04:00 发表:<br>两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 <br> 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 <br> 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。</span>, beContent=欢乐的树博士 2017-07-21 发表:: 研究方向:药物载体;基因; 接收率:约75% 审稿时间:约2个月 两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0dfa2208657, createdName=120ce422m02(暂无昵称), createdTime=Mon Aug 13 00:00:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093228, encodeId=256010932288b, content=选刊时需结合分区进行吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2194959, encodeId=067621949595d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:妇科肿瘤<br>经验分享:投了第二天旧送审了,2.5送审,3.11悲剧,理由:找了三十个审稿人,没人审稿,真无语。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0c02582555, createdName=zhangqiccmu, createdTime=Sun Mar 24 03:11:43 CST 2024, time=2024-03-24, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2107636, encodeId=b4a2210e6362e, content=挺好的杂志,做外泌体miRNA治疗方向,投了别的五六分期刊都被拒了,投这个至少给外审了,希望能有好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bea5414925, createdName=ms1000001212608631, createdTime=Tue Dec 27 10:54:27 CST 2022, time=2022-12-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1003273, encodeId=9e0910032e370, content=偏重的研究方向:基因<br>经验分享:cancer medicine推荐转投,确定转投以后好几天一直没消息呢,大家有类似经历吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Wed Jul 28 11:04:37 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
    2014-02-27 匿名用户

    审稿速度:3.0 | 投稿命中率:75.0
    经验分享:4个figure,一审周期约3个月,大修三个月后返回很快小修,小修几天返回很快接受,从投稿到接受约5个月左右……

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2121135, encodeId=5b6721211359d, content=请问各位初审Under Review多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf9c5290959, createdName=14862b90m09(暂无昵称), createdTime=Wed Mar 22 16:27:37 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=590987, encodeId=667d59098ec9, content=投了篇生信,被转到别的杂志。最后还是拒绝。写给大家做个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=560e5151026, createdName=14697858m50(暂无昵称), createdTime=Sat May 16 00:00:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093227, encodeId=8b7a109322e8c, content=SCI期刊是如何分区的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188004, encodeId=0e802188004e9, content=审稿速度:6.0<br>偏重的研究方向:胰腺炎<br>经验分享:审稿速度非常慢,一审2个月,2审3个月还在进行中,且发邮件不回复,太难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ce1740495, createdName=扒坏蛋糕, createdTime=Sun Feb 18 17:08:21 CST 2024, time=2024-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=501404, encodeId=28c850140423, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:4个figure,一审周期约3个月,大修三个月后返回很快小修,小修几天返回很快接受,从投稿到接受约5个月左右……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Feb 27 11:19:00 CST 2014, time=2014-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560053, encodeId=7a06560053e1, content=不选择onlineopen就不收费吗?<span class="quote">欢乐的树博士 2017-07-21 发表::<br>研究方向:药物载体;基因; 接收率:约75% 审稿时间:约2个月 两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。</span><span class="quote">欢乐的树博士 2017-07-21 15:04:00 发表:<br>两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 <br> 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 <br> 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。</span>, beContent=欢乐的树博士 2017-07-21 发表:: 研究方向:药物载体;基因; 接收率:约75% 审稿时间:约2个月 两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0dfa2208657, createdName=120ce422m02(暂无昵称), createdTime=Mon Aug 13 00:00:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093228, encodeId=256010932288b, content=选刊时需结合分区进行吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2194959, encodeId=067621949595d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:妇科肿瘤<br>经验分享:投了第二天旧送审了,2.5送审,3.11悲剧,理由:找了三十个审稿人,没人审稿,真无语。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0c02582555, createdName=zhangqiccmu, createdTime=Sun Mar 24 03:11:43 CST 2024, time=2024-03-24, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2107636, encodeId=b4a2210e6362e, content=挺好的杂志,做外泌体miRNA治疗方向,投了别的五六分期刊都被拒了,投这个至少给外审了,希望能有好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bea5414925, createdName=ms1000001212608631, createdTime=Tue Dec 27 10:54:27 CST 2022, time=2022-12-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1003273, encodeId=9e0910032e370, content=偏重的研究方向:基因<br>经验分享:cancer medicine推荐转投,确定转投以后好几天一直没消息呢,大家有类似经历吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Wed Jul 28 11:04:37 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
    2018-08-13 120ce422m02(暂无昵称)

    不选择onlineopen就不收费吗?欢乐的树博士 2017-07-21 发表::
    研究方向:药物载体;基因; 接收率:约75% 审稿时间:约2个月 两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。
    欢乐的树博士 2017-07-21 15:04:00 发表:
    两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。
    由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。
    杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。

    欢乐的树博士 2017-07-21 发表:: 研究方向:药物载体;基因; 接收率:约75% 审稿时间:约2个月 两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2121135, encodeId=5b6721211359d, content=请问各位初审Under Review多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf9c5290959, createdName=14862b90m09(暂无昵称), createdTime=Wed Mar 22 16:27:37 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=590987, encodeId=667d59098ec9, content=投了篇生信,被转到别的杂志。最后还是拒绝。写给大家做个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=560e5151026, createdName=14697858m50(暂无昵称), createdTime=Sat May 16 00:00:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093227, encodeId=8b7a109322e8c, content=SCI期刊是如何分区的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188004, encodeId=0e802188004e9, content=审稿速度:6.0<br>偏重的研究方向:胰腺炎<br>经验分享:审稿速度非常慢,一审2个月,2审3个月还在进行中,且发邮件不回复,太难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ce1740495, createdName=扒坏蛋糕, createdTime=Sun Feb 18 17:08:21 CST 2024, time=2024-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=501404, encodeId=28c850140423, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:4个figure,一审周期约3个月,大修三个月后返回很快小修,小修几天返回很快接受,从投稿到接受约5个月左右……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Feb 27 11:19:00 CST 2014, time=2014-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560053, encodeId=7a06560053e1, content=不选择onlineopen就不收费吗?<span class="quote">欢乐的树博士 2017-07-21 发表::<br>研究方向:药物载体;基因; 接收率:约75% 审稿时间:约2个月 两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。</span><span class="quote">欢乐的树博士 2017-07-21 15:04:00 发表:<br>两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 <br> 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 <br> 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。</span>, beContent=欢乐的树博士 2017-07-21 发表:: 研究方向:药物载体;基因; 接收率:约75% 审稿时间:约2个月 两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0dfa2208657, createdName=120ce422m02(暂无昵称), createdTime=Mon Aug 13 00:00:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093228, encodeId=256010932288b, content=选刊时需结合分区进行吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2194959, encodeId=067621949595d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:妇科肿瘤<br>经验分享:投了第二天旧送审了,2.5送审,3.11悲剧,理由:找了三十个审稿人,没人审稿,真无语。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0c02582555, createdName=zhangqiccmu, createdTime=Sun Mar 24 03:11:43 CST 2024, time=2024-03-24, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2107636, encodeId=b4a2210e6362e, content=挺好的杂志,做外泌体miRNA治疗方向,投了别的五六分期刊都被拒了,投这个至少给外审了,希望能有好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bea5414925, createdName=ms1000001212608631, createdTime=Tue Dec 27 10:54:27 CST 2022, time=2022-12-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1003273, encodeId=9e0910032e370, content=偏重的研究方向:基因<br>经验分享:cancer medicine推荐转投,确定转投以后好几天一直没消息呢,大家有类似经历吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Wed Jul 28 11:04:37 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
    2021-12-29 桑晒麦拉

    选刊时需结合分区进行吗?

    1

    展开1条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2121135, encodeId=5b6721211359d, content=请问各位初审Under Review多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf9c5290959, createdName=14862b90m09(暂无昵称), createdTime=Wed Mar 22 16:27:37 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=590987, encodeId=667d59098ec9, content=投了篇生信,被转到别的杂志。最后还是拒绝。写给大家做个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=560e5151026, createdName=14697858m50(暂无昵称), createdTime=Sat May 16 00:00:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093227, encodeId=8b7a109322e8c, content=SCI期刊是如何分区的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188004, encodeId=0e802188004e9, content=审稿速度:6.0<br>偏重的研究方向:胰腺炎<br>经验分享:审稿速度非常慢,一审2个月,2审3个月还在进行中,且发邮件不回复,太难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ce1740495, createdName=扒坏蛋糕, createdTime=Sun Feb 18 17:08:21 CST 2024, time=2024-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=501404, encodeId=28c850140423, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:4个figure,一审周期约3个月,大修三个月后返回很快小修,小修几天返回很快接受,从投稿到接受约5个月左右……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Feb 27 11:19:00 CST 2014, time=2014-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560053, encodeId=7a06560053e1, content=不选择onlineopen就不收费吗?<span class="quote">欢乐的树博士 2017-07-21 发表::<br>研究方向:药物载体;基因; 接收率:约75% 审稿时间:约2个月 两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。</span><span class="quote">欢乐的树博士 2017-07-21 15:04:00 发表:<br>两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 <br> 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 <br> 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。</span>, beContent=欢乐的树博士 2017-07-21 发表:: 研究方向:药物载体;基因; 接收率:约75% 审稿时间:约2个月 两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0dfa2208657, createdName=120ce422m02(暂无昵称), createdTime=Mon Aug 13 00:00:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093228, encodeId=256010932288b, content=选刊时需结合分区进行吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2194959, encodeId=067621949595d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:妇科肿瘤<br>经验分享:投了第二天旧送审了,2.5送审,3.11悲剧,理由:找了三十个审稿人,没人审稿,真无语。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0c02582555, createdName=zhangqiccmu, createdTime=Sun Mar 24 03:11:43 CST 2024, time=2024-03-24, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2107636, encodeId=b4a2210e6362e, content=挺好的杂志,做外泌体miRNA治疗方向,投了别的五六分期刊都被拒了,投这个至少给外审了,希望能有好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bea5414925, createdName=ms1000001212608631, createdTime=Tue Dec 27 10:54:27 CST 2022, time=2022-12-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1003273, encodeId=9e0910032e370, content=偏重的研究方向:基因<br>经验分享:cancer medicine推荐转投,确定转投以后好几天一直没消息呢,大家有类似经历吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Wed Jul 28 11:04:37 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
    2024-03-24 zhangqiccmu 来自湖北省

    审稿速度:2.0 | 投稿命中率:25.0
    偏重的研究方向:妇科肿瘤
    经验分享:投了第二天旧送审了,2.5送审,3.11悲剧,理由:找了三十个审稿人,没人审稿,真无语。

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2121135, encodeId=5b6721211359d, content=请问各位初审Under Review多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf9c5290959, createdName=14862b90m09(暂无昵称), createdTime=Wed Mar 22 16:27:37 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=590987, encodeId=667d59098ec9, content=投了篇生信,被转到别的杂志。最后还是拒绝。写给大家做个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=560e5151026, createdName=14697858m50(暂无昵称), createdTime=Sat May 16 00:00:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093227, encodeId=8b7a109322e8c, content=SCI期刊是如何分区的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188004, encodeId=0e802188004e9, content=审稿速度:6.0<br>偏重的研究方向:胰腺炎<br>经验分享:审稿速度非常慢,一审2个月,2审3个月还在进行中,且发邮件不回复,太难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ce1740495, createdName=扒坏蛋糕, createdTime=Sun Feb 18 17:08:21 CST 2024, time=2024-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=501404, encodeId=28c850140423, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:4个figure,一审周期约3个月,大修三个月后返回很快小修,小修几天返回很快接受,从投稿到接受约5个月左右……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Feb 27 11:19:00 CST 2014, time=2014-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560053, encodeId=7a06560053e1, content=不选择onlineopen就不收费吗?<span class="quote">欢乐的树博士 2017-07-21 发表::<br>研究方向:药物载体;基因; 接收率:约75% 审稿时间:约2个月 两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。</span><span class="quote">欢乐的树博士 2017-07-21 15:04:00 发表:<br>两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 <br> 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 <br> 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。</span>, beContent=欢乐的树博士 2017-07-21 发表:: 研究方向:药物载体;基因; 接收率:约75% 审稿时间:约2个月 两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0dfa2208657, createdName=120ce422m02(暂无昵称), createdTime=Mon Aug 13 00:00:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093228, encodeId=256010932288b, content=选刊时需结合分区进行吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2194959, encodeId=067621949595d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:妇科肿瘤<br>经验分享:投了第二天旧送审了,2.5送审,3.11悲剧,理由:找了三十个审稿人,没人审稿,真无语。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0c02582555, createdName=zhangqiccmu, createdTime=Sun Mar 24 03:11:43 CST 2024, time=2024-03-24, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2107636, encodeId=b4a2210e6362e, content=挺好的杂志,做外泌体miRNA治疗方向,投了别的五六分期刊都被拒了,投这个至少给外审了,希望能有好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bea5414925, createdName=ms1000001212608631, createdTime=Tue Dec 27 10:54:27 CST 2022, time=2022-12-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1003273, encodeId=9e0910032e370, content=偏重的研究方向:基因<br>经验分享:cancer medicine推荐转投,确定转投以后好几天一直没消息呢,大家有类似经历吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Wed Jul 28 11:04:37 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
    2022-12-27 ms1000001212608631 来自上海

    挺好的杂志,做外泌体miRNA治疗方向,投了别的五六分期刊都被拒了,投这个至少给外审了,希望能有好结果

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2121135, encodeId=5b6721211359d, content=请问各位初审Under Review多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf9c5290959, createdName=14862b90m09(暂无昵称), createdTime=Wed Mar 22 16:27:37 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=590987, encodeId=667d59098ec9, content=投了篇生信,被转到别的杂志。最后还是拒绝。写给大家做个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=560e5151026, createdName=14697858m50(暂无昵称), createdTime=Sat May 16 00:00:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093227, encodeId=8b7a109322e8c, content=SCI期刊是如何分区的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2188004, encodeId=0e802188004e9, content=审稿速度:6.0<br>偏重的研究方向:胰腺炎<br>经验分享:审稿速度非常慢,一审2个月,2审3个月还在进行中,且发邮件不回复,太难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ce1740495, createdName=扒坏蛋糕, createdTime=Sun Feb 18 17:08:21 CST 2024, time=2024-02-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=501404, encodeId=28c850140423, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:4个figure,一审周期约3个月,大修三个月后返回很快小修,小修几天返回很快接受,从投稿到接受约5个月左右……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=470, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Feb 27 11:19:00 CST 2014, time=2014-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560053, encodeId=7a06560053e1, content=不选择onlineopen就不收费吗?<span class="quote">欢乐的树博士 2017-07-21 发表::<br>研究方向:药物载体;基因; 接收率:约75% 审稿时间:约2个月 两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。</span><span class="quote">欢乐的树博士 2017-07-21 15:04:00 发表:<br>两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 <br> 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 <br> 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。</span>, beContent=欢乐的树博士 2017-07-21 发表:: 研究方向:药物载体;基因; 接收率:约75% 审稿时间:约2个月 两个月内收到审稿意见,审稿人极其认真,提了非常多的宝贵意见,收获很大。 由于补充的实验较多,申请了延期修回,编辑很nice,在请求的时间基础上,多给了一周时间。 杂志社的效率挺高的,虽然IF不高,也是一次愉快的投稿经历。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0dfa2208657, createdName=120ce422m02(暂无昵称), createdTime=Mon Aug 13 00:00:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093228, encodeId=256010932288b, content=选刊时需结合分区进行吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2194959, encodeId=067621949595d, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:妇科肿瘤<br>经验分享:投了第二天旧送审了,2.5送审,3.11悲剧,理由:找了三十个审稿人,没人审稿,真无语。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0c02582555, createdName=zhangqiccmu, createdTime=Sun Mar 24 03:11:43 CST 2024, time=2024-03-24, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2107636, encodeId=b4a2210e6362e, content=挺好的杂志,做外泌体miRNA治疗方向,投了别的五六分期刊都被拒了,投这个至少给外审了,希望能有好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bea5414925, createdName=ms1000001212608631, createdTime=Tue Dec 27 10:54:27 CST 2022, time=2022-12-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1003273, encodeId=9e0910032e370, content=偏重的研究方向:基因<br>经验分享:cancer medicine推荐转投,确定转投以后好几天一直没消息呢,大家有类似经历吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4d02501413, createdName=沧海医僧笑, createdTime=Wed Jul 28 11:04:37 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
    2021-07-28 沧海医僧笑

    偏重的研究方向:基因
    经验分享:cancer medicine推荐转投,确定转投以后好几天一直没消息呢,大家有类似经历吗

    0

共26条页码: 1/3页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分